Literature DB >> 27016602

Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs.

Ning Yang1, James S Gibbs1, Heather D Hickman1, Glennys V Reynoso1, Arun K Ghosh2, Jack R Bennink1, Jonathan W Yewdell3.   

Abstract

Influenza A virus gene segment 7 encodes two proteins: the M1 protein translated from unspliced mRNA and the M2 protein produced by mRNA splicing and largely encoded by the M1 +1 reading frame. To better understand the generation of defective ribosomal products relevant to MHC class I Ag presentation, we engineered influenza A virus gene segment 7 to encode the model H-2 K(b) class I peptide ligand SIINFEKL at the M2 protein C terminus. Remarkably, after treating virus-infected cells with the RNA splicing inhibitor spliceostatin A to prevent M2 mRNA generation, K(b)-SIINFEKL complexes were still presented on the cell surface at levels ≤60% of untreated cells. Three key findings indicate that SIINFEKL is produced by cytoplasmic translation of unspliced M1 mRNA initiating at CUG codons within the +1 reading frame: 1) synonymous mutation of CUG codons in the M2-reading frame reduced K(b)-SIINFEKL generation; 2) K(b)-SIINFEKL generation was not affected by drug-mediated inhibition of AUG-initiated M1 synthesis; and 3) K(b)-SIINFEKL was generated in vitro and in vivo from mRNA synthesized in the cytoplasm by vaccinia virus, and hence cannot be spliced. These findings define a viral defective ribosomal product generated by cytoplasmic noncanonical translation and demonstrate the participation of CUG-codon-based translation initiation in pathogen immunosurveillance.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27016602      PMCID: PMC4868770          DOI: 10.4049/jimmunol.1502303

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Anti-peptide antibody blocks peptide binding to MHC class I molecules in the endoplasmic reticulum.

Authors:  C J Hilton; A M Dahl; K L Rock
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

Review 2.  Rethinking peptide supply to MHC class I molecules.

Authors:  Laurence C Eisenlohr; Lan Huang; Tania N Golovina
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

3.  Initiation of translation at CUG, GUG, and ACG codons in mammalian cells.

Authors:  H Mehdi; E Ono; K C Gupta
Journal:  Gene       Date:  1990-07-16       Impact factor: 3.688

4.  A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas.

Authors:  S R Hann; M W King; D L Bentley; C W Anderson; R N Eisenman
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

5.  A novel influenza A virus mitochondrial protein that induces cell death.

Authors:  W Chen; P A Calvo; D Malide; J Gibbs; U Schubert; I Bacik; S Basta; R O'Neill; J Schickli; P Palese; P Henklein; J R Bennink; J W Yewdell
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 6.  The gene structure and replication of influenza virus.

Authors:  R A Lamb; P W Choppin
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

7.  Nuclear export of influenza A virus mRNAs requires ongoing RNA polymerase II activity.

Authors:  Maria-Joao Amorim; Eliot K Read; Rosa M Dalton; Liz Medcalf; Paul Digard
Journal:  Traffic       Date:  2006-11-21       Impact factor: 6.215

8.  Viral alteration of cellular translational machinery increases defective ribosomal products.

Authors:  Peter Berglund; Diana Finzi; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

9.  Systematic search fails to detect immunogenic MHC class-I-restricted determinants encoded by influenza A virus noncoding sequences.

Authors:  Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  Virology       Date:  2003-01-05       Impact factor: 3.616

10.  Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames.

Authors:  Sylvain Cardinaud; Arnaud Moris; Michèle Février; Pierre-Simon Rohrlich; Laurence Weiss; Pierre Langlade-Demoyen; François A Lemonnier; Olivier Schwartz; André Habel
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

View more
  11 in total

1.  Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Authors:  Jiajie Wei; Rigel J Kishton; Matthew Angel; Crystal S Conn; Nicole Dalla-Venezia; Virginie Marcel; Anne Vincent; Frédéric Catez; Sabrina Ferré; Lilia Ayadi; Virginie Marchand; Devin Dersh; James S Gibbs; Ivaylo P Ivanov; Nathan Fridlyand; Yohann Couté; Jean-Jacques Diaz; Shu-Bing Qian; Louis M Staudt; Nicholas P Restifo; Jonathan W Yewdell
Journal:  Mol Cell       Date:  2019-01-31       Impact factor: 17.970

2.  Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.

Authors:  Gabriela L Cosma; Jenna L Lobby; Elizabeth J Fay; Nicholas A Siciliano; Ryan A Langlois; Laurence C Eisenlohr
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

Review 3.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

4.  Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.

Authors:  Damien J Zanker; Sara Oveissi; David C Tscharke; Mubing Duan; Siyuan Wan; Xiaomu Zhang; Kun Xiao; Nicole A Mifsud; James Gibbs; Lenny Izzard; Daniel Dlugolenski; Pierre Faou; Karen L Laurie; Nathalie Vigneron; Ian G Barr; John Stambas; Benoît J Van den Eynde; Jack R Bennink; Jonathan W Yewdell; Weisan Chen
Journal:  J Immunol       Date:  2019-05-15       Impact factor: 5.422

5.  Influenza A Virus Negative Strand RNA Is Translated for CD8+ T Cell Immunosurveillance.

Authors:  Heather D Hickman; Jacqueline W Mays; James Gibbs; Ivan Kosik; Javier G Magadán; Kazuyo Takeda; Suman Das; Glennys V Reynoso; Barbara F Ngudiankama; JiaJie Wei; John P Shannon; Daniel McManus; Jonathan W Yewdell
Journal:  J Immunol       Date:  2018-07-16       Impact factor: 5.422

6.  Comprehensive profiling of translation initiation in influenza virus infected cells.

Authors:  Heather M Machkovech; Jesse D Bloom; Arvind R Subramaniam
Journal:  PLoS Pathog       Date:  2019-01-23       Impact factor: 6.823

7.  The Hidden Enemy Within: Non-canonical Peptides in Virus-Induced Autoimmunity.

Authors:  Manivel Lodha; Florian Erhard; Lars Dölken; Bhupesh K Prusty
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

8.  Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.

Authors:  Shira Weingarten-Gabbay; Susan Klaeger; Siranush Sarkizova; Leah R Pearlman; Da-Yuan Chen; Kathleen M E Gallagher; Matthew R Bauer; Hannah B Taylor; W Augustine Dunn; Christina Tarr; John Sidney; Suzanna Rachimi; Hasahn L Conway; Katelin Katsis; Yuntong Wang; Del Leistritz-Edwards; Melissa R Durkin; Christopher H Tomkins-Tinch; Yaara Finkel; Aharon Nachshon; Matteo Gentili; Keith D Rivera; Isabel P Carulli; Vipheaviny A Chea; Abishek Chandrashekar; Cansu Cimen Bozkus; Mary Carrington; Nina Bhardwaj; Dan H Barouch; Alessandro Sette; Marcela V Maus; Charles M Rice; Karl R Clauser; Derin B Keskin; Daniel C Pregibon; Nir Hacohen; Steven A Carr; Jennifer G Abelin; Mohsan Saeed; Pardis C Sabeti
Journal:  Cell       Date:  2021-06-03       Impact factor: 66.850

Review 9.  Flu DRiPs in MHC Class I Immunosurveillance.

Authors:  Jiajie Wei; Jonathan W Yewdell
Journal:  Virol Sin       Date:  2018-11-19       Impact factor: 4.327

10.  The Effect of Interferons on Presentation of Defective Ribosomal Products as HLA Peptides.

Authors:  Liran Komov; Dganit Melamed Kadosh; Eilon Barnea; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2021-06-01       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.